Every 10-Q that UFP Technologies Inc (UFPT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow UFPT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full UFPT filings page.
UFP Technologies, Inc. reported solid growth for the quarter ended June 30, 2026. Net sales rose 15.1% to $174.0 million, driven mainly by Surfaces and Support, Cardiovascular, Infection Control, and Orthopedics sub‑markets, with organic sales growth of 12.4%. Gross margin improved to 29.3% from 28.8%, supporting operating income of $28.1 million and net income of $20.9 million, or $2.68 diluted EPS.
For the first six months of 2026, net sales increased 9.6% to $328.2 million, and net income reached $38.3 million ($4.92 diluted EPS). Cash from operations declined to $18.8 million as receivables and inventories expanded with higher volumes. Cash was $9.0 million and total debt $117.3 million under a $275 million credit facility, with a 5.0% weighted average interest rate and covenant compliance. The business remains highly concentrated, with two customers accounting for over 20% each of sales, and management notes an ongoing AJR workforce transition and a February 2026 cyber incident that has not materially impacted operations to date.
UFP Technologies reported solid first-quarter 2026 results with modest growth and continued strength in its medical business. Net sales rose to $154.2 million from $148.1 million, driven by 5.9% higher sales to medical customers, especially in robotic surgery, patient surfaces, and interventional and surgical products. Non-medical revenue declined 15%.
Gross margin edged up to 28.8%, supported by efficiencies in robotic surgery. Net income increased slightly to $17.5 million, or $2.24 diluted EPS, compared with $17.2 million and $2.21 a year earlier. Two major customers accounted for 24.8% and 22.1% of net sales, underscoring meaningful customer concentration.
Operating cash flow was $3.2 million, as higher receivables and inventory absorbed cash despite strong earnings. Cash stood at $20.0 million, and total debt under the company’s $275 million credit facility was $137.6 million at a roughly 5.0% average interest rate, with all covenants met.
Management highlighted reduced tariff impacts and expects future refunds via vendor credits after recent U.S. court decisions. A February 2026 cyber incident did not materially affect systems or results, though the company cautions that future cybersecurity issues could pose risks.
UFP Technologies (UFPT) reported steady Q3 performance with strong year‑to‑date momentum. Net sales were $154.6 million versus $145.2 million a year ago, and net income was $16.4 million compared with $16.4 million. For the first nine months, sales rose to $453.9 million from $360.4 million, with net income up to $50.7 million from $42.6 million as recent acquisitions contributed meaningfully.
Gross profit increased in Q3 to $42.7 million, though operating income softened to $23.4 million. Diluted EPS was $2.11 in Q3 and $6.52 year‑to‑date. Operating cash flow strengthened to $75.1 million for the nine months, supporting lower borrowings under the credit facilities. Total debt was $146.1 million at quarter‑end, and cash was $18.2 million. Medical end‑markets comprised 92.1% of Q3 sales, reflecting the company’s focus on single‑use medical devices.
UFPT continued integrating acquisitions. In 2025 it acquired Techno Plastics Industries for $4.5 million and Universal Plastics & Engineering Company for $7.5 million. 2024 acquisitions included AJR Enterprises ($110.0 million), Welch Fluorocarbon ($34.6 million), AQF (€43 million), and Marble Medical ($4.5 million). Customer concentration remained notable, with two customers accounting for 27.1% and 17.1% of Q3 sales.
UFP Technologies reported significant revenue and profit growth driven largely by recent acquisitions while facing margin pressure, higher interest expense, and customer concentration.
Net sales were $151.2 million for the quarter (up 37.2% year-over-year) and $299.3 million for the six months (up 39.1%). Net income was $17.2 million in the quarter and $34.4 million year-to-date, with diluted EPS of $2.21 for the quarter and $4.42 for six months. Gross margin declined to 28.8% in Q2 from 30.0% due to higher material, labor and onboarding inefficiencies at newly acquired AJR operations. SG&A rose in absolute dollars but decreased as a percentage of sales to 12.4% in Q2.
The company completed multiple acquisitions that expanded its medical-market capabilities and geography, including AJR Enterprises ($110.7M), AQF ($47.7M), Welch ($35.2M), Marble ($5.0M) and AJR Specialty ($2.8M); these collectively contributed about $76.3M in sales in H1 2025. Long-term debt outstanding was $163.6 million with Q2 interest expense of $2.7 million; cash from operations was $39.1 million for six months. Management disclosed contingent consideration obligations, tariff exposure estimated at ~$9 million annually, and customer concentration with two customers representing ~27.4% and ~20.3% of Q2 sales.